Investigating a new tau aggregation inhibitor “RE01” in PS19 transgenic mice
Dilek Mercan, Arush Baijal, Fabrizio Musacchio, Julia Steffen, Andrea Baral, Yvonne Schleehuber, Lisa Marie Ramirez, Ina Vorberg, Markus Zweckstetter, Martin Fuhrmann · FENS Forum 2024
Alzheimer’s disease (AD), which is characterized by extracellular accumulation of amyloid-beta peptide and intracellular aggregation of hyperphosphorylated tau, is the most common form of dementia. During AD pathogenesis, tau is abnormally phosphorylated and aggregating within neurons. As a result of continuous intraneuronal tau aggregation, neurofibrillary tangles are formed. The aim of our project is to determine, whether inhibiting tau protein aggregation with a novel anti-aggregative compound “RE01” improves survival, behavior and neuropathology in a tau-transgenic mouse model. RE01 is an
ePoster · Neuroscience